Here's How Much Upside Eli Lilly Stock Has, According to Analysts

Core Viewpoint - Eli Lilly has experienced significant stock growth, with a 400% increase over the past five years, but its high valuation raises questions about future investment potential [2]. Group 1: Stock Performance and Valuation - Eli Lilly's current market cap exceeds $800 billion, and it trades at approximately 40 times its trailing earnings [2]. - The consensus analyst price target for Eli Lilly is slightly over $1,221, indicating a potential upside of about 35% from its current price [6]. - Despite a 16% decline in stock value this year, Eli Lilly has been underperforming compared to the S&P 500 [9]. Group 2: Earnings and Growth Potential - In the fourth quarter of 2025, Eli Lilly reported a 43% increase in sales to $19.3 billion and a 50% rise in net income to $6.6 billion, driven by its popular GLP-1 drugs, Mounjaro and Zepbound [7]. - Analysts maintain a bullish outlook, with 25 out of the last 30 ratings being buy ratings, reflecting strong growth expectations [6][8]. - Long-term investors may see even stronger returns if Eli Lilly continues to lead in the GLP-1 market [8].